ArticlePediatric nephrology (Berlin, Germany)2026
Risk factors for loss of Varicella immunity after pediatric kidney transplantation.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVaricella zoster (VZV) vaccination pre-kidney transplant (Tx) can help prevent severe disseminated VZV in immunosuppressed recipients; however, studies have shown loss of humoral immunity post-Tx.
methodsA retrospective analysis of 45 pediatric kidney Tx recipients with positive pre-Tx VZV IgG (>1.09 index). VZV IgG was assessed annually and compared with the induction agent used, the number of VZV vaccines received, and the interval between the last dose of VZV vaccine and Tx.
resultsMedian age at Tx was 16.7 years (IQR 12.7-18.5). 11 of 45 (24.4%) patients lost immunity to VZV at a median of 12.6 months post-Tx. Those who lost VZV immunity were younger at the time of Tx, 12.4 years vs. 17.3 years (P = 0.05) and more likely to be on steroid-based immunosuppression 81.8% vs. 32.4% (P = 0.006). There were no differences between the induction agents used and the ability to maintain VZV IgG antibodies. Subjects who required ≥3 doses of VZV vaccine to develop VZV IgG seropositivity were at a higher risk for losing their anti-varicella antibody post-Tx (HR 3.81, 95% CI 1.09-13.30, P = 0.04). Receiving VZV vaccination <1 year prior to kidney Tx was associated with a higher risk for losing anti-varicella antibody after Tx (HR 6.97, 95% CI 2.08-23.34).
conclusionIn this small cohort, pediatric kidney Tx recipients are more likely to lose VZV IgG in those who were younger at the time of Tx, on steroid-based immunosuppression, required 3 or more doses of VZV vaccination to seroconvert, or received VZV vaccine <1 year before Tx.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.